Ionis Pharmaceuticals will reduce the annual Wholesale Acquisition Cost of TRYNGOLZA (olezarsen) to $40,000 starting April 1, ahead of a potential FDA decision for severe hypertriglyceridemia on June 30.
Written By: Pharmacally Medical News Desk
Ionis Pharmaceuticals has announced a significant price reduction for TRYNGOLZA® (olezarsen), lowering the drug’s annual Wholesale Acquisition Cost (WAC) to $40,000 effective April 1. The revised pricing will apply to the currently approved indication in familial chylomicronemia syndrome (FCS) and is expected to remain the same if the therapy receives approval for severe hypertriglyceridemia (sHTG).
The company said the pricing decision reflects the clinical value demonstrated by olezarsen and aims to support broader and sustained patient access. Ionis noted that the new WAC aligns with findings from landmark Phase 3 data published in the New England Journal of Medicine and follows extensive consultations with healthcare providers and payers.
Olezarsen is currently the first and only investigational therapy for severe hypertriglyceridemia shown to significantly reduce triglyceride levels and lower the risk of acute pancreatitis, a serious complication associated with extremely high triglycerides.
Ionis said the price adjustment ahead of the FDA action date scheduled for June 30 is intended to allow payers and health systems to incorporate the therapy into 2027 contracting cycles, positioning the company for a smoother launch and faster patient access if the new indication is approved.
Severe hypertriglyceridemia is defined by triglyceride levels of 500 mg/dL or higher and is associated with a significantly increased risk of acute pancreatitis and other serious complications. Current standard-of-care therapies and lifestyle interventions, including diet and exercise, often fail to adequately control triglyceride levels in many patients.
The condition affects more than 3 million people in the United States, including approximately 1 million individuals considered at the highest risk of complications, highlighting the need for more effective treatment options.
Reference
Ionis statement about the Wholesale Acquisition Cost of TRYNGOLZA® (olezarsen), 25 March 2026, https://ir.ionis.com/static-files/ebde7dc2-f02f-4285-813c-fb744951c848